Oxaliplatin hypersensitivity: Evaluation, implications of skin testing, and desensitization

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 1, 2014, Pages 40-45

  Wong, Johnson T ^a   Ling, Morris ^a   Patil, Sarita ^a   Banerji, Aleena ^a   Long, Aidan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carboplatin; Cisplatin; Continuous; Desensitization; Hypersensitivity; Intravenous; Onset; Oxaliplatin; Skin test

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TUMOR; HEMOLYTIC ANEMIA; HOARSENESS; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION RATE; LOW BACK PAIN; LUNG DISEASE; MALE; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PROGNOSIS; PRURITUS; RETROSPECTIVE STUDY; RIGOR; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SKIN DISEASE; SKIN TEST; SOMNOLENCE; THROAT TIGHTNESS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL IMPAIRMENT; VOMITING;

CARBOPLATIN; CARBOPLATIN HYPERSENSITIVITY; CAS; CIS; CISPLATIN; CISPLATIN HYPERSENSITIVITY; CONTINUOUS; DESENSITIZATION; DIHA; DITP; DRUG-INDUCED HEMOLYTIC ANEMIA; DRUG-INDUCED THROMBOCYTOPENIA; GASTROINTESTINAL; GI; HIGH-RISK PROTOCOL; HRP; HSR; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IG; IMMUNOGLOBULIN; INTERMEDIATE PROTOCOL; INTRAVENOUS; IP; ONSET; OXALIPLATIN; OXALIPLATIN HYPERSENSITIVITY; OXS; RAPID PROTOCOL; RP; SKIN TEST;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BOSTON; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; HOSPITALS, GENERAL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN TESTS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891657716     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.08.011     Document Type: Article

References (27)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
2. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
3. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
4. Go R.S., Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17:409-422.
5. Colombo N., Guthrie D., Chiari S., Parmar M., Qian W., Swart A.M., et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003, 95:125-132.
6. Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003, 95:105-112.
7. Mori Y., Nishimura T., Kitano T., Yoshimura K., Matsumoto S., Kanai M., et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 2010, 79:136-143.
8. Shibata Y., Ariyama H., Baba E., Takii Y., Esaki T., Mitsugi K., et al. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 2009, 14:397-401.
9. Yanai T., Iwasa S., Hashimoto H., Kato K., Hamaguchi T., Yamada Y., et al. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer. Anticancer Res 2012, 32:5521-5526.
10. Syrigou E.I., Karapanagiotou E.M., Alamara C.V., Boura P.G., Saif M.W., Syrigos K.N. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 2009, 8:106-109.
11. Siu S.W., Chan R.T., Au G.K. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006, 17:259-261.
12. Shao Y.Y., Hu F.C., Liang J.T., Chiu W.T., Cheng A.L., Yang C.H. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc 2010, 109:362-368.
13. Seki K., Senzaki K., Tsuduki Y., Ioroi T., Fujii M., Yamauchi H., et al. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011, 8:210-215.
14. Polyzos A., Tsavaris N., Gogas H., Souglakos J., Vambakas L., Vardakas N., et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009, 76:36-41.
15. Kim M.Y., Kang S.Y., Lee S.Y., Yang M.S., Kim M.H., Song W.J., et al. Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. Asian Pac J Cancer Prev 2012, 13:1209-1215.
16. Kim B.H., Bradley T., Tai J., Budman D.R. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009, 76:231-238.
17. Gowda A., Goel R., Berdzik J., Leichman C.G., Javle M. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004, 18:1671-1675. discussion 6, 80, 83-4.
18. Brandi G., Pantaleo M.A., Galli C., Falcone A., Antonuzzo A., Mordenti P., et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003, 89:477-481.
19. Castells M.C., Tennant N.M., Sloane D.E., Hsu F.I., Barrett N.A., Hong D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008, 122:574-580.
20. Hesterberg P.E., Banerji A., Oren E., Penson R.T., Krasner C.N., Seiden M.V., et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009, 123:1262-1267.e1.
21. Lee C.W., Matulonis U.A., Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004, 95:370-376.
22. Lee C.W., Matulonis U.A., Castells M.C. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005, 99:393-399.
23. Patil S.U., Long A.A., Ling M., Wilson M.T., Hesterberg P., Wong J.T., et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 2012, 129:443-447.
24. Garufi C., Cristaudo A., Vanni B., Bria E., Aschelter A.M., Santucci B., et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003, 14:497-498.
25. Wong J.T., Ripple R.E., MacLean J.A., Marks D.R., Bloch K.J. Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol. J Allergy Clin Immunol 1994, 94:189-194.
26. Zhao M., Isami K., Nakamura S., Shirakawa H., Nakagawa T., Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012, 8:55.
27. Descoeur J., Pereira V., Pizzoccaro A., Francois A., Ling B., Maffre V., et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 2011, 3:266-278.